Skip to main content
번역 진행 중 — 귀하의 언어 버전을 준비하는 동안 이 콘텐츠가 영어로 표시됩니다.

How could using smarter, real-time clinical trials change drug development and patient care?

Healthcare
United States
April 29, 2026에 시작됨

“For the first time, FDA regulators will be able to see what’s happening in a clinical trial, looking at endpoints in the cloud as they occur,” writes FDA commissioner

Need to find a specific claim? Search all statements.
🗳️ Join the conversation
3 투표할 진술 • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (7+ recommended) 3/7
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM 게시자: will Apr 29, 2026
As we consider the shift to smarter trials, we must evaluate the balance between innovation and ethical considerations. Are we prepared to address the unintended consequences that may arise from rapid changes in drug development?

번역 대기 중

Vote options for this statement: agree, disagree, or unsure
Vote to see results
CLAIM 게시자: will Apr 29, 2026
The implementation of real-time clinical trials raises important questions about regulatory oversight. How will the FDA ensure that the integrity of the data is maintained when it is continuously monitored and accessed?

번역 대기 중

Vote options for this statement: agree, disagree, or unsure
Vote to see results
CLAIM 게시자: will Apr 29, 2026
While real-time clinical trials may enhance efficiency, there are concerns about data privacy and the potential for bias in interpretation. If regulators can access data continuously, will there be sufficient safeguards to ensure that patient confidentiality is maintained?

번역 대기 중

Vote options for this statement: agree, disagree, or unsure
Vote to see results

💡 How This Works

  • Add Statements: Post claims or questions (10-500 characters)
  • Vote: Agree, Disagree, or Unsure on each statement
  • Respond: Add detailed pro/con responses with evidence
  • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us